Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The median age at symptom onset in the cohort was 55 years, ranging from 16 to 81 years. Data from patients’ initial ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

Las acciones de las empresas farmacéuticas cayeron en todo el mundo después de que el presidente de EE.UU., Donald Trump, ...

The complete response (CR) rate at 1 month improved from 25% with single-fraction conformal 3D RT (3D-CRT) to 37% with SBRT, ...

Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...

Among the safety stocks discussed by Cramer during the episode on May 14, Bristol-Myers Squibb Company (NYSE:BMY) was first ...

President Donald Trump is attempting to slash drug prices for Americans by more closely aligning their costs to lower prices ...

Although the Trump administration's healthcare policies pose risks for Bristol-Myers Squibb, the chaos opens a contrarian door for BMY stock.

Bristol-Myers Squibb Co. prevailed against investor allegations it misled them about a payout tied to Food and Drug ...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are ...

Bristol Myers CEO Christopher Boerner advocates global cost-sharing for drug R&D and criticizes PBMs. Read nore here.